Nia Impact Advisors LLC Invests $1.48 Million in GeneDx Holdings Corp. (NASDAQ:WGS)

Nia Impact Advisors LLC purchased a new position in GeneDx Holdings Corp. (NASDAQ:WGS) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 19,256 shares of the company’s stock, valued at approximately $1,480,000. Nia Impact Advisors LLC owned about 0.07% of GeneDx as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. MCF Advisors LLC raised its stake in GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock worth $27,000 after buying an additional 182 shares during the period. Sterling Capital Management LLC grew its holdings in shares of GeneDx by 877.8% in the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock valued at $27,000 after acquiring an additional 316 shares in the last quarter. Global Retirement Partners LLC bought a new position in shares of GeneDx in the 4th quarter valued at about $28,000. MetLife Investment Management LLC grew its holdings in shares of GeneDx by 6.2% in the 4th quarter. MetLife Investment Management LLC now owns 7,750 shares of the company’s stock valued at $596,000 after acquiring an additional 453 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new position in shares of GeneDx in the 4th quarter valued at about $35,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Trading Up 3.3%

GeneDx stock opened at $60.93 on Wednesday. GeneDx Holdings Corp. has a 52 week low of $19.16 and a 52 week high of $117.75. The stock has a market capitalization of $1.71 billion, a P/E ratio of -31.09 and a beta of 1.96. The stock has a 50-day simple moving average of $88.77 and a 200 day simple moving average of $82.83. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.17. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The company had revenue of $87.12 million during the quarter, compared to analysts’ expectations of $79.90 million. Analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Insider Transactions at GeneDx

In other GeneDx news, Director Keith A. Meister bought 100,000 shares of the business’s stock in a transaction on Thursday, May 8th. The stock was purchased at an average cost of $56.01 per share, for a total transaction of $5,601,000.00. Following the completion of the purchase, the director now directly owns 3,008,629 shares of the company’s stock, valued at approximately $168,513,310.29. This trade represents a 3.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Kevin Feeley sold 388 shares of the company’s stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $113.09, for a total value of $43,878.92. Following the sale, the chief financial officer now owns 3,337 shares of the company’s stock, valued at $377,381.33. The trade was a 10.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 139,390 shares of company stock worth $13,043,288 over the last quarter. Company insiders own 27.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. The Goldman Sachs Group raised their price objective on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a report on Wednesday, February 19th. Wells Fargo & Company reduced their price target on GeneDx from $105.00 to $78.00 and set an “equal weight” rating for the company in a report on Thursday, May 1st. Jefferies Financial Group upgraded GeneDx from a “hold” rating to a “buy” rating and set a $80.00 price target for the company in a report on Friday, May 9th. Finally, TD Securities reduced their price target on GeneDx from $135.00 to $110.00 and set a “buy” rating for the company in a report on Thursday, May 1st. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, GeneDx presently has an average rating of “Moderate Buy” and a consensus price target of $86.57.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.